Literature DB >> 26740062

Evaluating Individual Change With the Quality of Life in Neurological Disorders (Neuro-QoL) Short Forms.

Allan J Kozlowski1, David Cella2, Kristian P Nitsch3, Allen W Heinemann4.   

Abstract

OBJECTIVE: To provide a clinically useful means of interpreting change for individual patients on the Quality of Life in Neurological Disorders (Neuro-QoL) adult short forms (SFs) by applying a classical test theory concept for interpreting individual change.
DESIGN: Secondary analysis of existing data.
SETTING: Community. PARTICIPANTS: Persons with neurologic conditions including stroke, epilepsy, amyotrophic lateral sclerosis, multiple sclerosis, and Parkinson disease residing in community settings.
INTERVENTIONS: Not applicable. MAIN OUTCOME MEASURES: Neuro-QoL SFs for Applied Cognition-General Concerns, Applied Cognition-Executive Function, Applied Cognition-Combined, Ability to Participate in Social Roles and Activities, Satisfaction With Social Roles and Activities, Positive Affect and Well-Being, Depression, Stigma, Upper Extremity Function (Fine Motor, Activities of Daily Living), Lower Extremity Function (Mobility), Anxiety, Sleep Disturbance, Fatigue, and Emotional and Behavioral Dyscontrol. We estimated conditional minimal detectable change (cMDC) indices from the pooled SEs adjusted for a 95% confidence interval using the average of the SEs for any given pair of scores multiplied by the z score, or ([SE(Score1) + SE(Score2)]/2) * (1.96) * (SQRT(2)).
RESULTS: The cMDC indices are generally smallest in the midrange of all scales, ranging from 3.6 to 11.2 T-score points, and higher on the outer quartiles ranging from 3.7 to 21.6 T-score points. The lowest midrange cMDCs were for Satisfaction With Social Roles and Activities (3.6-4.7 T-score points), and the largest were for Sleep Disturbance (9.4-11.2 T-score points).
CONCLUSIONS: Change indices can help clinicians and investigators identify differences for individual patients or subjects that are large enough to motivate treatment change. cMDCs can reduce misclassification of magnitudes of change that are near the margins of error across the range of the Neuro-QoL SFs.
Copyright © 2016 American Congress of Rehabilitation Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Nervous system diseases; Patient outcome assessment; Psychometrics; Quality of life; Rehabilitation

Mesh:

Year:  2015        PMID: 26740062      PMCID: PMC4994512          DOI: 10.1016/j.apmr.2015.12.010

Source DB:  PubMed          Journal:  Arch Phys Med Rehabil        ISSN: 0003-9993            Impact factor:   3.966


  5 in total

1.  Evidence of validity for the Foot and Ankle Ability Measure (FAAM).

Authors:  Robroy L Martin; James J Irrgang; Ray G Burdett; Stephen F Conti; Jessie M Van Swearingen
Journal:  Foot Ankle Int       Date:  2005-11       Impact factor: 2.827

2.  Defining the minimum level of detectable change for the Roland-Morris questionnaire.

Authors:  P W Stratford; J Binkley; P Solomon; E Finch; C Gill; J Moreland
Journal:  Phys Ther       Date:  1996-04

Review 3.  Longitudinal construct validity: establishment of clinical meaning in patient evaluative instruments.

Authors:  M H Liang
Journal:  Med Care       Date:  2000-09       Impact factor: 2.983

4.  Neuro-QOL: brief measures of health-related quality of life for clinical research in neurology.

Authors:  D Cella; J-S Lai; C J Nowinski; D Victorson; A Peterman; D Miller; F Bethoux; A Heinemann; S Rubin; J E Cavazos; A T Reder; R Sufit; T Simuni; G L Holmes; A Siderowf; V Wojna; R Bode; N McKinney; T Podrabsky; K Wortman; S Choi; R Gershon; N Rothrock; C Moy
Journal:  Neurology       Date:  2012-05-09       Impact factor: 9.910

5.  Reliability, validity and administrative burden of the community reintegration of injured service members computer adaptive test (CRIS-CAT)".

Authors:  Linda Resnik; Matthew Borgia; Pensheng Ni; Paul A Pirraglia; Alan Jette
Journal:  BMC Med Res Methodol       Date:  2012-09-17       Impact factor: 4.615

  5 in total
  18 in total

1.  Differential Effects of Time to Initiation of Therapy on Disability and Quality of Life in Patients With Mild and Moderate to Severe Ischemic Stroke.

Authors:  Robert L Askew; Carmen E Capo-Lugo; Andrew Naidech; Shyam Prabhakaran
Journal:  Arch Phys Med Rehabil       Date:  2020-05-22       Impact factor: 3.966

2.  The value of patient-reported outcome measures for multiple sclerosis.

Authors:  Marisa P McGinley; Brittany Lapin
Journal:  Mult Scler       Date:  2022-09       Impact factor: 5.855

3.  Revisiting the Concept of Minimal Detectable Change for Patient-Reported Outcome Measures.

Authors:  Bryant A Seamon; Steven A Kautz; Mark G Bowden; Craig A Velozo
Journal:  Phys Ther       Date:  2022-08-04

4.  Patient Experience in Clinical Trials: Quality of Life, Financial Burden, and Perception of Care in Patients With Multiple Myeloma or Lymphoma Enrolled on Clinical Trials Compared With Standard Care.

Authors:  Surbhi Sidana; Cristine Allmer; Melissa C Larson; Amylou Dueck; Kathleen Yost; Rahma Warsame; Gita Thanarajasingam; James R Cerhan; Jonas Paludo; S Vincent Rajkumar; Thomas M Habermann; Grzegorz S Nowakowski; Yi Lin; Morie A Gertz; Thomas Witzig; Angela Dispenzieri; Wilson I Gonsalves; Stephen M Ansell; Carrie A Thompson; Shaji K Kumar
Journal:  JCO Oncol Pract       Date:  2022-05-17

5.  Longitudinal Patient Reported Outcomes with CAR-T Cell Therapy Versus Autologous and Allogeneic Stem Cell Transplant.

Authors:  Surbhi Sidana; Amylou C Dueck; Gita Thanarajasingam; Joan M Griffin; Carrie Thompson; Urshila Durani; Michelle Burtis; Rahma Warsame; Jonas Paludo; Morie A Gertz; Angela Dispenzieri; Stephen M Ansell; S Vincent Rajkumar; Kathleen Yost; Nora Bennani; Yi Lin; Shaji Kumar
Journal:  Transplant Cell Ther       Date:  2022-05-09

6.  Automated symptom and treatment side effect monitoring for improved quality of life among adults with diabetic peripheral neuropathy in primary care: a pragmatic, cluster, randomized, controlled trial.

Authors:  A S Adams; J A Schmittdiel; A Altschuler; E A Bayliss; R Neugebauer; L Ma; W Dyer; J Clark; B Cook; D Willyoung; M Jaffe; J D Young; E Kim; J M Boggs; L A Prosser; E Wittenberg; B Callaghan; M Shainline; R M Hippler; R W Grant
Journal:  Diabet Med       Date:  2018-11-07       Impact factor: 4.359

7.  Psychometric properties and responsiveness of Neuro-QoL Cognitive Function in persons with Huntington disease (HD).

Authors:  Noelle E Carlozzi; Nicholas R Boileau; Jane S Paulsen; Nancy R Downing; Rebecca Ready; Joel S Perlmutter; David Cella; Kelvin L Chou; Michael K McCormack; Stacey Barton; Jin-Shei Lai
Journal:  Qual Life Res       Date:  2019-12-18       Impact factor: 4.147

8.  The Relationship between Dialysis Metrics and Patient-Reported Cognition, Fatigue, and Physical Function.

Authors:  Daniel A Sturgill; Naveet Bal; Sneha Nagavally; Dawn F Wolfgram
Journal:  Kidney Dis (Basel)       Date:  2020-07-10

9.  Longitudinal Change in Quality of Life in Neurological Disorders Measures Over 3 Years in Patients with Early Parkinson's Disease.

Authors:  Connie Marras; Kelly A Mills; Shirley Eberly; David Oakes; Kelvin L Chou; Matthew Halverson; Sotirios A Parashos; Christopher G Tarolli; Jin-Shei Lai; Cindy J Nowinsky; Oksana Suchowersky; Eric S Farbman; Lisa M Shulman; Tanya Simuni
Journal:  Mov Disord       Date:  2021-05-13       Impact factor: 9.698

10.  Clinical Use of PROMIS, Neuro-QoL, TBI-QoL, and Other Patient-Reported Outcome Measures for Individual Adult Clients with Cognitive and Language Disorders.

Authors:  Matthew L Cohen; Alyssa M Lanzi; Aaron J Boulton
Journal:  Semin Speech Lang       Date:  2021-07-14       Impact factor: 1.734

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.